Abstract | BACKGROUND: MATERIAL AND METHODS: RESULTS:
Alogliptin treatment significantly increased plasma glucagon-like peptide-1 (GLP-1) levels from 1.16 ± 1.71 pmol/L to 4.48 ± 1.53 pmol/L and significantly reduced levels of plasma glucose recorded 2 h after lunch and hemoglobin A1c (HbA1c). No significant differences were seen in insulin secretory ability of homeostasis model assessment (HOMA) (HOMA-β) and insulin resistance index of HOMA (HOMA-R) before and after alogliptin treatment. In contrast, alogliptin treatment significantly decreased plasma glucagon levels, from 116.1 ± 38.7 pg/mL to 89.6 ± 17.3 pg/mL. Moreover, there were significant correlations among HbA1c, GLP-1, and glucagon levels. CONCLUSIONS:
|
Authors | Naro Ohashi, Naoko Tsuji, Yoshitaka Naito, Takamasa Iwakura, Shinsuke Isobe, Masafumi Ono, Tomoyuki Fujikura, Takayuki Tsuji, Yukitoshi Sakao, Hideo Yasuda, Akihiko Kato, Yoshihide Fujigaki |
Journal | Medical science monitor : international medical journal of experimental and clinical research
(Med Sci Monit)
Vol. 20
Pg. 587-93
(Apr 10 2014)
ISSN: 1643-3750 [Electronic] United States |
PMID | 24717767
(Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Glycated Hemoglobin A
- Piperidines
- Steroids
- Uracil
- Glucagon-Like Peptide 1
- Glucagon
- alogliptin
|
Topics |
- Aged
- Asian People
- Body Mass Index
- Female
- Glucagon
(blood)
- Glucagon-Like Peptide 1
(metabolism)
- Glycated Hemoglobin
(metabolism)
- Humans
- Hyperglycemia
(chemically induced, drug therapy)
- Japan
- Kidney Function Tests
- Male
- Piperidines
(pharmacology, therapeutic use)
- Regression Analysis
- Renal Insufficiency, Chronic
(blood, drug therapy, physiopathology)
- Steroids
(adverse effects)
- Uracil
(analogs & derivatives, pharmacology, therapeutic use)
- Vital Signs
(drug effects)
|